Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots:

• Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors
• The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis
• NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and inflammatory disorders

Click here to read full press release/ article | Ref: Jecure Therapeutics | Image: Xconomy